Contraception
Volume 82, Issue 1 , Pages 95-101 , July 2010

Safety of contraceptive use among women with peripartum cardiomyopathy: a systematic review

Received 1 February 2010 ,Accepted 2 February 2010.

References 

  1. Pearson GD, Veille JC, Rahimtoola S, et al. Peripartum cardiomyopathy: National Heart, Lung, and Blood Institute and Office of Rare Diseases (National Institutes of Health) workshop recommendations and review. JAMA. 2000;283:1183–1188
  2. Homans DC. Peripartum cardiomyopathy. N Engl J Med. 1985;312:1432–1437
  3. Felker GM, Jaeger CJ, Klodas E, et al. Myocarditis and long-term survival in peripartum cardiomyopathy. Am Heart J. 2000;140:785–791
  4. Witlin AG, Mabie WC, Sibai BM. Peripartum cardiomyopathy: an ominous diagnosis. Am J Obstet Gynecol. 1997;176:182–188
  5. Modi KA, Illum S, Jariatul K, Caldito G, Reddy PC. Poor outcome of indigent patients with peripartum cardiomyopathy in the United States. Am J Obstet Gynecol. 2009;201:171.e1–171.e5
  6. Elkayam U, Akhter MW, Singh H, et al. Pregnancy-associated cardiomyopathy: clinical characteristics and a comparison between early and late presentation. Circulation. 2005;111:2050–2055
  7. Whitehead SJ, Berg CJ, Chang J. Pregnancy-related mortality due to cardiomyopathy: United States, 1991–1997. Obstet Gynecol. 2003;102:1326–1331
  8. Bhakta P, Biswas BK, Banerjee B. Peripartum cardiomyopathy: review of the literature. Yonsei Med J. 2007;48:731–747
  9. Elkayam U. Pregnant again after peripartum cardiomyopathy: to be or not to be?. Eur Heart J. 2002;23:753–756
  10. World Health Organization . Medical eligibility criteria for contraceptive use. 3rd ed. Geneva: World Health Organization; 2004;Available from: http://www.who.int/reproductive-health/publications/mec/mec.pdf
  11. World Health Organization . Medical eligibility criteria for contraceptive use, 2008 Update. Geneva: World Health Organization; 2008. Available from: http://www.who.int/reproductive-health/publications/mec/mec_update_2008.pdf
  12. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. Am J Prev Med. 2001;20:21–35
  13. Taurelle R, Ruet C, Jaupart F, Magnier S. [Contraception using a progestagen-only minipill in cardiac patients]. Arch Mal Coeur Vaiss. 1979;72:98–106
  14. Avila WS, Grinberg M, Melo NR, Aristodemo Pinotti J, Pileggi F. [Contraceptive use in women with heart disease]. Arq Bras Cardiol. 1996;66:205–211
  15. Suri V, Aggarwal N, Kaur R, Chaudhary N, Ray P, Grover A. Safety of intrauterine contraceptive device (copper T 200 B) in women with cardiac disease. Contraception. 2008;78:315–318
  16. Gupta S, Harding K. Contraception and cardiovascular disorders. Br J Fam Plann. 1999;25:13–17
  17. Preedy JR, Aitken EH. The effect of estrogen on water and electrolyte metabolism. III. Cardiac and renal disease. J Clin Invest. 1956;35:443–451
  18. Stachenfeld NS, Taylor HS. Effects of estrogen and progesterone administration on extracellular fluid. J Appl Physiol. 2004;96:1011–1018
  19. Fruzzetti F, Lello S, Lazzarini V, et al. The oral contraceptive containing 30 microg of ethinylestradiol plus 3 mg of drospirenone is able to antagonize the increase of extracellular water occurring in healthy young women during the luteal phase of the menstrual cycle: an observational study. Contraception. 2007;75:199–203
  20. Endrikat J, Sandri M, Gerlinger C, Rubig A, Schmidt W, Fortier M. A Canadian multicentre prospective study on the effects of an oral contraceptive containing 3 mg drospirenone and 30 microg ethinyl oestradiol on somatic and psychological symptoms related to water retention and on body weight. Eur J Contracept Reprod Health Care. 2007;12:220–228
  21. Machado RB, Tachotti F, Cavenague G, Maia E. Effects of two different oral contraceptives on total body water: a randomized study. Contraception. 2006;73:344–347
  22. Walling M. A multicenter efficacy and safety study of an oral contraceptive containing 150 micrograms desogestrel and 30 micrograms ethinyl estradiol. Contraception. 1992;46:313–326
  23. Kessler KM, Warde DA, Ledis JE, Kessler RM. Left ventricular size and function in women receiving oral contraceptives. Obstet Gynecol. 1980;55:211–214
  24. Bibbins-Domingo K, Lin F, Vittinghoff E, et al. Effect of hormone therapy on mortality rates among women with heart failure and coronary artery disease. Am J Cardiol. 2005;95:289–291
  25. Lindenfeld J, Ghali JK, Krause-Steinrauf HJ, et al. Hormone replacement therapy is associated with improved survival in women with advanced heart failure. J Am Coll Cardiol. 2003;42:1238–1245
  26. Reis SE, Holubkov R, Young JB, White BG, Cohn JN, Feldman AM. Estrogen is associated with improved survival in aging women with congestive heart failure: analysis of the vesnarinone studies. J Am Coll Cardiol. 2000;36:529–533
  27. Neinstein LS, Katz B. Contraception and cardiac disease: can the pill, IUD be prescribed. Contracept Technol Update. 1984;5:118–120
  28. Thorne S, Nelson-Piercy C, MacGregor A, et al. Pregnancy and contraception in heart disease and pulmonary arterial hypertension. J Fam Plann Reprod Health Care. 2006;32:75–81
  29. Farmer M, Webb A. Intrauterine device insertion-related complications: can they be predicted?. J Fam Plann Reprod Health Care. 2003;29:227–231
  30. Aznar R, Gamiz R, Ley E, Reynoso L, De Leon MD. [Induction of vagal reflex with the insertion of intrauterine devices]. Ginecol Obstet Mex. 1974;36:169–173
  31. Aznar R, Reynoso L, Ley E, Gamez R, De Leon MD. Electrocardiographic changes induced by insertion of an intrauterine device and other uterine manipulations. Fertil Steril. 1976;27:92–96
  32. Sherrod DB, Nicholl W. Electrocardiographic changes during intrauterine contraceptive device insertion. Am J Obstet Gynecol. 1974;119:1044–1051
  33. Acker D, Boehm FH, Askew DE, Rothman H. Electrocardiogram changes with intrauterine contraceptive device insertion. Am J Obstet Gynecol. 1973;115:458–461
  34. Romhilt DW, Chaffin C, Choi SC, Irby EC. Arrhythmias on ambulatory electrocardiographic monitoring in women without apparent heart disease. Am J Cardiol. 1984;54:582–586
  35. Kirwan JR, McSorley D, Wynn V. Electrocardiographic abnormalities in women taking oral contraceptives. Lancet. 1977;2:562
  36. Sagay AS, Okeahialam BN, Imade GE. Electrocardiographic changes among Nigerian Norplant users. West Afr J Med. 2002;21:146–148
  37. Dinger JC, Heinemann LA, Kuhl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception. 2007;75:344–354
  38. Gammage MD, Libman L, Littler WA. Insertion of intrauterine contraceptive device in a patient with a ventricular septal defect: need for antibiotic prophylaxis. Br Med J (Clin Res Ed). 1984;289:1516–1517
  39. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007;116:1736–1754

☆ The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

PII: S0010-7824(10)00048-X

doi: 10.1016/j.contraception.2010.02.004

Contraception
Volume 82, Issue 1 , Pages 95-101 , July 2010

Article Tools